CN107232601A - 一种玛咖保健片及其制备方法 - Google Patents
一种玛咖保健片及其制备方法 Download PDFInfo
- Publication number
- CN107232601A CN107232601A CN201710416221.0A CN201710416221A CN107232601A CN 107232601 A CN107232601 A CN 107232601A CN 201710416221 A CN201710416221 A CN 201710416221A CN 107232601 A CN107232601 A CN 107232601A
- Authority
- CN
- China
- Prior art keywords
- maca
- squalene
- health
- root powder
- pueraria root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000000759 Lepidium meyenii Species 0.000 title claims abstract description 44
- 235000000421 Lepidium meyenii Nutrition 0.000 title claims abstract description 43
- 235000012902 lepidium meyenii Nutrition 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims description 9
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract description 37
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract description 37
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229940031439 squalene Drugs 0.000 claims abstract description 37
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000000843 powder Substances 0.000 claims abstract description 27
- 241000219780 Pueraria Species 0.000 claims abstract description 26
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 241000234295 Musa Species 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000011122 softwood Substances 0.000 claims description 5
- 238000002137 ultrasound extraction Methods 0.000 claims description 5
- 235000020985 whole grains Nutrition 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 15
- 230000002929 anti-fatigue Effects 0.000 abstract description 11
- 235000013402 health food Nutrition 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000003507 refrigerant Substances 0.000 abstract description 2
- 235000019640 taste Nutrition 0.000 abstract description 2
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 239000000463 material Substances 0.000 description 10
- 230000009182 swimming Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000036299 sexual function Effects 0.000 description 3
- YVWMHFYOIJMUMN-CYZWUHAYSA-N (6e,8e)-5-oxooctadeca-6,8-dienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C(=O)CCCC(O)=O YVWMHFYOIJMUMN-CYZWUHAYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000251774 Squalus Species 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000004383 glucosinolate group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 241000554155 Andes Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 241000691769 Centroscyllium fabricii Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010020466 Hunger Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- -1 triterpene alkenes Chemical class 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种玛咖保健片,通过将具有抗疲劳功效的玛咖粉和角鲨烯配合使用,产生了优异的协同增效作用,同时,采用片剂的形式制备保健食品,方便携带,使用便利,起到了较好的抗疲劳效果,并且使用香蕉香精具有清凉的口感掩盖了其他组分的不良味道,使得保健片易于让消费者接受。
Description
技术领域
本发明涉及保健食品领域,具体涉及一种玛咖保健片。
背景技术
玛咖(Lepidium meyenii Walp.,maca)是十字花科植物,原产于秘鲁中部4000米以上的安第斯山区,具有形似萝卜样的块根。玛咖营养丰富,富含蛋白质、糖类、脂肪酸、氨基酸以及独有的玛咖烯、玛咖酰胺等,有消除疲劳、增强精力、改善性功能、提高生育能力以及抗氧化等作用。玛咖在我国没有自然分布,玛咖原产地的自然环境和栽培条件与我国云南省丽江市非常相似。目前,国内玛咖的大面积种植集中在此。研究表明,云南栽培玛咖与秘鲁栽培玛咖成分种类基本相同,其中蛋白质、钙、铁以及Vc等对人体十分有益的成分较高,不饱和脂肪酸占脂肪酸的比例较高。
玛咖含有多种营养成分且含量丰富。目前,有研究发现,玛咖中含有玛咖酰胺、玛咖烯、芥子油苷等活性成分。实验证明,玛咖具有抗疲劳、改善性功能、抗氧化、减少前列腺增生以及提高生育能力等多种功效,且无毒、食用安全。研究表明,秘鲁玛咖粉的营养成分,结果显示,其营养成分合理,是一种具较高营养价值的食品,是一种可进一步引种和开发的资源。由于玛咖具有显著的保健医疗功效,目前国内对于玛咖功效性能方面研究主要集中在生物碱、多糖等方面。
玛咖营养物质含量高,结构合理,同时含有多种生物活性成分,所以使玛咖具备多种营养保健功能。玛咖中含有的氨基酸、牛磺酸、锌等物质,使其具有抗疲劳和预防贫血作用,类固醇以及促肾上腺素类物质可以缓解哮喘症,生物碱、甾醇、皂甙等物质与人体内分泌有关,可以缓解更年期综合症。玛咖烯、玛咖酰胺、芥子油苷和异硫氰酸苄酯对于改善动物性功能有着积极的作用。所以,玛咖传统上可用于增强精力、提高生育力、改善性功能;芥子油苷和异硫氰酸苄酯已被报道具有抗癌效果,玛咖中含有的多不饱、脂肪酸和VC也具有抗癌辅助作用。
角鲨烯又名鲨烯、三十碳六烯、鱼肝油萜,化学名为(6E,10E,14E,18E)-2,6,10,15,19,23-六甲基-2,6,10,14,18,22-二十四碳六烯,是一种高度不饱和烃类化合物。角鲨烯最初由日本化学家Tsujimoto于1906年在黑鲨鱼肝油中发现,主要来自深海鲨鱼肝油,占脂质含量90%以上,同时还少量存在于油脂不皂化物中,尤其在橄榄油、棕榈油及其脱臭馏出物中含量较多。角鲨烯是一种天然三萜烯类、多不饱和脂肪族烃类化合物,含有六个非共轭双键。
角鲨烯的药理作用主要涉及以下几个方面:(1)抗癌、抗肿瘤作用:角鲨烯具有极强供氧能力,可抑制癌细胞生成,防止癌细胞扩散和因化疗而白细胞减少,对胃癌、食道癌、肺癌,卵巢癌,具有明显疗效;(2)抗疲劳作用:疲劳是一种复杂生理生化过程,通常与代谢紊乱、自由基过多、免疫功能失调有关,角鲨烯具有消除自由基、调节免疫功能等作用,角鲨烯进入人体将迅速引起氧化作用,促使超氧化酶与乳酸脱氢酶显著升高,乳酸迅速分解,体内能量代谢旺盛,体力快速恢复,疲劳及时消除,同时,角鲨烯又使体内红细胞大增,可有效克服因缺氧所引起各种疾病;从而为组织细胞制造能量,为减轻体力疲劳创造充分物质基础;(3)抗心血管疾病:高血压、高血脂、高血粘是心脑血管疾病元凶,角鲨烯能促进血液循环,预防及治疗因血液循环不良而引起心脏病、高血压、低血压及中风等,对冠心病、心肌炎、心肌梗死等有显著缓解作用;(4)抗感染作用:角鲨烯具有渗透、扩散、杀菌作用,可用作杀菌剂,对白癣菌、大肠杆菌、痢疾杆菌、绿脓杆菌、金葡菌、溶血性链球菌及念珠菌等有杀灭和抑制作用,可预治细菌引起上呼吸道感染、皮肤病、耳鼻喉炎等,还可治疗湿疹、烫伤、放射性皮肤溃疡及口疮等。
现有技术中包含玛咖的保健食品逐渐增多,角鲨烯也常用于保健食品中,但是将两者合用的保健食品尚未见。因而,如何充分利用玛咖和角鲨烯的营养价值,开发具有优异保健功效的新产品,满足和丰富人们日益增长的物质需求,是保健食品领域亟待解决的问题。
发明内容
本发明的目的是克服上述缺陷,提供一种新的玛咖保健片,其以玛咖粉为主要的抗疲劳活性成分,配以同样具有抗疲劳作用的角鲨烯,具有优异的协同抗疲劳功效。
本发明解决该技术问题的技术方案是:
玛咖粉5~15%
角鲨烯5~15%
乳糖20~30%
微晶纤维素0.5~2%
香蕉香精0.5~2%
山梨醇1~2%
氢化植物油0.5~1%
余量为水。
所述玛咖粉的制备方法为:将玛咖原料干片粉碎过80目,超声提取后过滤,3000r/min离心1h,浓缩,干燥,即得。
所述玛咖粉和角鲨烯的重量比优选为1~3:3~1,优选为1:1。
所述保健片的制备方法为:
先将玛咖粉,角鲨烯和乳糖混合均匀,过80目筛,加入微晶纤维素、香蕉香精、山梨醇和水,制软材,过16目筛,干燥后得干颗粒,整粒,加入氢化植物油,混合均匀后压片即得。
本发明的有益效果:
(1)本发明将分别具有抗疲劳功效的玛咖粉和角鲨烯配合使用,产生了优异的协同增效作用。
(2)本发明采用片剂的形式制备保健食品,方便携带,使用便利,起到了较好的提抗疲劳效果,同时使用香蕉香精具有清凉的口感掩盖了其他组分的不良味道,从而使得保健片易于让消费者接受。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。除非另外说明,否则所有的百分数、比率、比例或份数按重量计。
除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
实施例1:
按如下重量配比称取各原料组份:
玛咖粉15%
角鲨烯5%
乳糖20%
微晶纤维素0.5%
香蕉香精2%
山梨醇1%
氢化植物油0.8%
余量为水。
其中,所述玛咖粉的制备方法为:
将玛咖原料干片100g粉碎过80目,超声提取后过滤,3000r/min离心1h,浓缩,干燥,即得。
先将玛咖粉,角鲨烯和乳糖混合均匀,过80目筛,加入微晶纤维素、香蕉香精、山梨醇和水,制软材,过16目筛,干燥后得干颗粒,整粒,加入氢化植物油,混合均匀后压片即得。
实施例2:
按如下重量配比称取各原料组份:
玛咖粉5%
角鲨烯15%
乳糖20%
微晶纤维素1%
香蕉香精1%
山梨醇1%
氢化植物油0.5%
余量为水。
其中,所述玛咖粉的制备方法为:
将玛咖原料干片100g粉碎过80目,超声提取后过滤,3000r/min离心1h,浓缩,干燥,即得。
先将玛咖粉,角鲨烯和乳糖混合均匀,过80目筛,加入微晶纤维素、香蕉香精、山梨醇和水,制软材,过16目筛,干燥后得干颗粒,整粒,加入氢化植物油,混合均匀后压片即得。
实施例3:
按如下重量配比称取各原料组份:
玛咖粉10%
角鲨烯10%
乳糖25%
微晶纤维素0.5%
香蕉香精0.5%
山梨醇1%
氢化植物油0.5%
余量为水。
其中,所述玛咖粉的制备方法为:
将玛咖原料干片100g粉碎过80目,超声提取后过滤,3000r/min离心1h,浓缩,干燥,即得。
先将玛咖粉,角鲨烯和乳糖混合均匀,过80目筛,加入微晶纤维素、香蕉香精、山梨醇和水,制软材,过16目筛,干燥后得干颗粒,整粒,加入氢化植物油,混合均匀后压片即得。
实施例4玛咖保健片的抗疲劳功能试验
将雄性昆明种小鼠,体重为18~22g,随机分为7组,各组10只,即空白对照组(蒸馏水),玛咖对照组(用玛咖粉等量替代实施例中的玛咖粉和角鲨烯制备的保健片),角鲨烯对照组(用角鲨烯等量替代实施例中的玛咖粉和角鲨烯制备的保健片),阴性对照组(根据实施例的配方不含玛咖粉和角鲨烯制备的空白片),实施例1、实施例2和实施例3制备得到的玛咖保健片,分别给予受试动物混悬液灌胃,每天灌胃一次,灌胃体积为0.1mL/10g·bw,连续灌胃30天,其中除空白对照组和阴性对照组不含活性成分以外,其他各组所含的活性成分为约1g,末次给药30min后,在小鼠尾根部负重5%体重的铅皮,将小鼠置于游泳箱中游泳,游泳箱水深30cm,水温25℃±1.0℃,记录小鼠负重游泳时间(s),即小鼠自游泳开始至死亡的时间,将记录的负重游泳时间用Excel、Spss软件进行统计学处理,结果如表1所示:
表1小鼠负重游泳时间试验(x±s;n=10)
组别 | 负重游泳时间 |
空白对照组 | 256.2±107.1 |
阴性对照组 | 254.8±113.2 |
玛咖对照组 | 354.3±112.7 |
角鲨烯对照组 | 331.2±105.5 |
实施例1 | 478.9±109.2 |
实施例2 | 472.4±126.1 |
实施例3 | 482.3±102.6 |
结果显示,实施例1-3以及玛咖对照组和角鲨烯对照组与空白对照组相比,其负重游泳时间均明显延长,差异具有显著性,表明本发明的药物组合物有延长小鼠负重游泳时间的作用,同时,实施例1-3与玛咖对照组和角鲨烯对照组相比,其负重游泳时间也均明显延长,差异具有显著性,说明本发明提供的玛咖保健片较之单用玛咖粉或角鲨烯,具有良好的协同增效作用。
以上所述仅为本发明的较佳实施例而已,并非用以限定本发明的实质技术内容范围,本发明的实质技术内容是广义地定义于申请的权利要求范围中,任何他人完成的技术实体或方法,若是与申请的权利要求范围所定义的完全相同,也或是一种等效的变更,均将被视为涵盖于该权利要求范围之中。
Claims (5)
1.一种玛咖保健片,其特征在于,原料按重量百分比组成如下:
玛咖粉5~15%
角鲨烯5~25%
乳糖20~30%
微晶纤维素0.5~2%
香蕉香精0.5~2%
山梨醇1~2%
氢化植物油0.5~1%
余量为水。
2.根据权利要求1所述的一种玛咖保健片,其特征在于,所述玛咖粉的制备方法为:将玛咖原料干片粉碎过80目,超声提取后过滤,3000r/min离心1h,浓缩,干燥,即得。
3.根据权利要求1所述的一种玛咖保健片,其特征在于,所述玛咖粉和角鲨烯的重量比优选为1~3:3~1,最优选为1:1。
4.根据权利要求1-3任一项所述的一种玛咖保健片,其特征在于,原料按重量百分比组成如下:玛咖粉10%
角鲨烯10%
乳糖25%
微晶纤维素0.5%
香蕉香精0.5%
山梨醇1%
氢化植物油0.5%
余量为水。
5.根据权利要求1-4任一项所述的一种玛咖保健片的制备方法,其特征在于,先将玛咖粉,角鲨烯和乳糖混合均匀,过80目筛,加入微晶纤维素、香蕉香精、山梨醇和水,制软材,过16目筛,干燥,整粒,加入氢化植物油,混合均匀后压片即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710416221.0A CN107232601A (zh) | 2017-06-06 | 2017-06-06 | 一种玛咖保健片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710416221.0A CN107232601A (zh) | 2017-06-06 | 2017-06-06 | 一种玛咖保健片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107232601A true CN107232601A (zh) | 2017-10-10 |
Family
ID=59984895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710416221.0A Pending CN107232601A (zh) | 2017-06-06 | 2017-06-06 | 一种玛咖保健片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107232601A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103238842A (zh) * | 2013-05-21 | 2013-08-14 | 天津兰瑞生物技术有限公司 | 一种鲎卵和玛咖保健片剂及其制备方法 |
CN104544104A (zh) * | 2015-02-11 | 2015-04-29 | 昆明轿子雪山玛卡生物科技开发有限公司 | 一种玛卡与海狗油复合软胶囊 |
-
2017
- 2017-06-06 CN CN201710416221.0A patent/CN107232601A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103238842A (zh) * | 2013-05-21 | 2013-08-14 | 天津兰瑞生物技术有限公司 | 一种鲎卵和玛咖保健片剂及其制备方法 |
CN104544104A (zh) * | 2015-02-11 | 2015-04-29 | 昆明轿子雪山玛卡生物科技开发有限公司 | 一种玛卡与海狗油复合软胶囊 |
Non-Patent Citations (1)
Title |
---|
王旭霞等: "《"氧"生疗百病》", 31 August 2011 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meireles et al. | A review of properties, nutritional and pharmaceutical applications of Moringa oleifera: integrative approach on conventional and traditional Asian medicine | |
CN102450618B (zh) | 一种黑蒜的制作方法 | |
CN103444911A (zh) | 一种药食同源养生保健调和油 | |
CN104605287A (zh) | 一种含支链氨基酸的黑果腺肋花楸食品 | |
CN102144748A (zh) | 具有排毒护肝养颜功能的五色面制食品 | |
CN106118870A (zh) | 一种营养保健茶油 | |
CN106359657A (zh) | 一种营养均衡的食用调和油 | |
CN105925421B (zh) | 一种防治更年期综合征的金花葵保健酒及其制备方法 | |
CN102349608A (zh) | 一种清咽润喉的保健品组合物及其制备方法 | |
CN102178055B (zh) | 用于防止脂肪酸败的饲料组合物及其制备方法 | |
CN111000252A (zh) | 一种减脂且营养均衡的代餐食品及其制备方法 | |
CN103651949A (zh) | 一种养生减肥型调和油 | |
CN101735918A (zh) | 一种富硒养生酒及其生产方法 | |
CN103168813A (zh) | 一种红景天苦荞饼干及其制作方法 | |
CN101564180A (zh) | 核桃全营养素及含其的软胶囊和保健品 | |
RU2489038C1 (ru) | Продукт диетического, профилактического и функционального питания при хронической ишемии головного мозга человека | |
CN107006806A (zh) | 一种秋葵胶囊 | |
CN106417678A (zh) | 一种高品质食用油脂组合物 | |
CN103396251A (zh) | 高硒锗健身强体红薯 | |
CN106213130A (zh) | 无致敏无添加剂健脑强身菌藻复合营养米粉及其生产方法 | |
CN107232601A (zh) | 一种玛咖保健片及其制备方法 | |
KR101458823B1 (ko) | 천연 발효물을 이용한 집중력향상 또는 성장발육촉진을 위한 건강기능식품 및 이의 제조방법 | |
CN109156804A (zh) | 一种海鲜专用酱油调味品及其制备方法 | |
KR20190118720A (ko) | 사철쑥을 주성분으로 하는 기능성 및 친환경성 돼지사료용 보조제와 그 제조방법, 그리고 이를 이용한 돼지사육방법 및 그 돈육 | |
CN104430720A (zh) | 黄秋葵、菌、藻植物组合物制作功能性饼干的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171010 |
|
RJ01 | Rejection of invention patent application after publication |